In brief
- A systematic review and meta-analysis aggregates seven randomized trials of MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD).
- Compared to controls, MDMA improves core PTSD symptoms, dissociation, depression, and functional impairment, though it does not improve sleep quality.
- The authors highlight limitations: small sample sizes, challenges with blinding, non-standardized therapies, and a single sponsor common to all trials.
A team from the University of Tasmania and the Uniformed Services University of the Health Sciences has published a meta-analysis on MDMA-assisted psychotherapy for PTSD in the Harvard Review of Psychiatry. Their conclusion is that this therapy can reduce the disorder’s symptoms and improve various areas of daily life, though the body of evidence remains fragile.
Seven trials, one sponsor
The authors searched ClinicalTrials.gov, MEDLINE, PsycInfo, PsycArticles, and the Cochrane Library from the inception of each database through June 2025. They selected seven randomized controlled trials—both published and unpublished—that compared MDMA-assisted therapy against a control: either low-dose MDMA or a placebo, both combined with psychotherapy.
An important methodological detail is that the included studies are not those affected by recent retractions in this field. The researchers explicitly note this distinction.
What improves and what does not
To measure the effect, the team calculated standardized mean differences on the Clinician-Administered PTSD Scale (CAPS) and mean differences in secondary measures. The result: MDMA therapy can significantly improve PTSD, dissociation, depression, and functional impairment compared to controls. No improvement was observed in sleep quality.
The summary of the work to which we have had access does not detail specific effect size figures, so we do not reproduce them here. The full text is behind a paywall.
Limitations acknowledged by the authors
The article lists four issues. Some trials have small sample sizes. Blinding is complicated in psychedelic studies. The psychotherapies employed were not standardized. And all the trials share a single sponsor, which reduces the independence of the collective findings.
Regarding blinding, in our news section, we previously covered an analysis suggesting that blinding fails in the vast majority of MDMA-placebo trials. It is a caveat worth keeping in mind when reading any meta-analysis in this area.
Implications
This work does not provide new patient data; it reorganizes existing information after excluding retracted trials. Its value lies in offering a comprehensive snapshot of the clinical landscape. The authors conclude that the results support MDMA-assisted therapy for core PTSD symptoms and quality-of-life measures, presenting it as an emerging treatment option.
For those who want to place these substances and their research in a general context, we have an overview on our page about MDMA and empathogens and another on the science of psychedelic therapy. The open question remains whether independent trials with more participants and better-defined therapies will confirm what this set of seven studies suggests.
Source
- Green WM, Raut SB, James FLJ, Benedek DM, Ursano RJ, Capaldi VF, Johnson LR. MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis. Harvard Review of Psychiatry, September 9, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
